Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Related Citations for PubMed (Select 24130051)

1.

Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.

Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M.

Mol Cancer Ther. 2013 Dec;12(12):2760-71. doi: 10.1158/1535-7163.MCT-13-0487. Epub 2013 Oct 15.

2.

Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.

Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, Tomaselli S, Gallo G, Catello S, Rivieccio V, Zetta L, Presta M.

J Cell Mol Med. 2010 Aug;14(8):2109-21. doi: 10.1111/j.1582-4934.2009.00855.x. Epub 2010 Jul 20.

PMID:
19627396
3.

Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.

Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, Amadori A, Mantovani A, Presta M.

Blood. 2004 Jul 1;104(1):92-9. Epub 2004 Mar 18.

4.

Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.

Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, Indraccolo S, Presta M.

Mol Cancer Ther. 2011 Sep;10(9):1600-10. doi: 10.1158/1535-7163.MCT-11-0286. Epub 2011 Jul 15.

5.

Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.

Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M.

J Pathol. 2013 Jun;230(2):228-38. doi: 10.1002/path.4181.

PMID:
23424081
6.

Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.

Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, Mantovani A, Giacca M, Presta M.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1837-42. Epub 2005 Jul 14.

7.

Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.

Leali D, Inforzato A, Ronca R, Bianchi R, Belleri M, Coltrini D, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M.

Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):696-703. doi: 10.1161/ATVBAHA.111.243998. Epub 2012 Jan 19.

8.

The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S.

PLoS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378. Epub 2012 Jul 20.

9.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

PMID:
20167562
10.

Up-regulation of hepatoma-derived growth factor facilitates tumor progression in malignant melanoma [corrected].

Tsai HE, Wu JC, Kung ML, Liu LF, Kuo LH, Kuo HM, Chen SC, Chan EC, Wu CS, Tai MH, Liu GS.

PLoS One. 2013;8(3):e59345. doi: 10.1371/journal.pone.0059345. Epub 2013 Mar 25. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/02369930-29de-4cd6-a059-9520af0be6b9.

11.

Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.

Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A.

J Pathol. 2013 Jan;229(1):87-98. doi: 10.1002/path.4081. Epub 2012 Oct 1.

PMID:
22847671
12.

Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice.

Margheri F, Serratì S, Lapucci A, Anastasia C, Giusti B, Pucci M, Torre E, Bianchini F, Calorini L, Albini A, Ventura A, Fibbi G, Del Rosso M.

Neoplasia. 2009 Oct;11(10):1106-15.

13.

Downregulation of hepatoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma.

Tsai HE, Liu GS, Kung ML, Liu LF, Wu JC, Tang CH, Huang CH, Chen SC, Lam HC, Wu CS, Tai MH.

Mol Cancer Ther. 2013 Jun;12(6):1016-25. doi: 10.1158/1535-7163.MCT-12-0832. Epub 2013 Mar 6.

14.

Up-regulating ribonuclease inhibitor inhibited epithelial-to-mesenchymal transition and metastasis in murine melanoma cells.

Pan X, Xiong D, Yao X, Xin Y, Zhang L, Chen J.

Int J Biochem Cell Biol. 2012 Jun;44(6):998-1008. doi: 10.1016/j.biocel.2012.03.008. Epub 2012 Mar 24.

PMID:
22465710
15.

Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells.

Lefèvre G, Babchia N, Calipel A, Mouriaux F, Faussat AM, Mrzyk S, Mascarelli F.

Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1047-57. doi: 10.1167/iovs.08-2378. Epub 2008 Nov 21.

16.

Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.

Leali D, Alessi P, Coltrini D, Rusnati M, Zetta L, Presta M.

Curr Pharm Des. 2009;15(30):3577-89. Review.

PMID:
19860702
17.

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J.

Br J Cancer. 2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25.

19.

Luteolin reduces the invasive potential of malignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition.

Ruan JS, Liu YP, Zhang L, Yan LG, Fan FT, Shen CS, Wang AY, Zheng SZ, Wang SM, Lu Y.

Acta Pharmacol Sin. 2012 Oct;33(10):1325-31. doi: 10.1038/aps.2012.93. Epub 2012 Sep 17.

20.

The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo.

Yu Y, Gao S, Li Q, Wang C, Lai X, Chen X, Wang R, Di J, Li T, Wang W, Wu X.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1321-8. doi: 10.1007/s00432-012-1201-7. Epub 2012 Apr 6.

PMID:
22481251
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk